The effect of denosumab for the treatment of osteoporosis in hemodialysis patients
Not Applicable
- Conditions
- Osteoporosis
- Registration Number
- JPRN-UMIN000014458
- Lead Sponsor
- Saiseikai Kumamoto Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Patient who have the contraindication for denosumab.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in bone mineral density (BMD) at lumbar supine and femoral neck and TRACP-5b
- Secondary Outcome Measures
Name Time Method Change in Ca, P, intact-PTH and side effect
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie denosumab's efficacy in hemodialysis-induced osteoporosis?
How does denosumab compare to bisphosphonates in managing osteoporosis among hemodialysis patients?
Are there specific biomarkers that predict denosumab response in chronic kidney disease-related osteoporosis?
What adverse events are associated with denosumab use in hemodialysis patients and how are they managed?
What are the potential combination therapies involving denosumab for enhanced bone density in renal failure patients?